Company / Interest Expense
Trevi Therapeutics, Inc. Interest Expense History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$391.0K
FY2023
5-year range
$391.0K / $1.2M
FY2019-FY2023
Trend
-66.4%
vs FY2022
Sector context
#38 of 44
Health Care
What the data says
Trevi Therapeutics, Inc.'s interest expense of $391,000 is lower than 86% of companies in the Health Care sector (FY2023). Improved from $1M to $391,000 over the past 2 years.
Based on SEC 10-K filings.
$391,000 in FY2023 with a 5-year CAGR of +17.6%.
Improved from $1M to $391,000 over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -5.0%
- 5-Year CAGR
- +17.6%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 44This company $391.0K Sector average $291.0M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.6%, indicating consistent growth.
- In FY2023, interest expense decreased 66.4% year-over-year.
- Ranks #38 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $391.0K | -66.4% |
| FY2022 | $1.2M | -3.2% |
| FY2021 | $1.2M | +163.6% |
| FY2020 | $456.0K | - |
| FY2019 | - | - |
| FY2018 | $174.0K | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026